KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases.

G A Whitfield, H Bulbeck, L Clifton-Hadley, D Edwards, S Jefferies, M D Jenkinson, M Griffin, J Handley, D Megias, P Sanghera, R Shaffer, S Short, W Wilson

Clin Oncol (R Coll Radiol) 36(11) 681-689

PMID39030085
PMCID-
DOI10.1016/j.clon.2024.07.001
发表日期2024-07-19
入排依据:This is a Phase II randomized trial of radiotherapy techniques (hippocampal sparing vs. conventional whole brain radiotherapy) for brain metastases. While it is oncology, human, randomized, and reports time-to-event endpoints (including overall survival as a secondary endpoint), it fails the required criteria because: 1) It is a Phase II trial, not Phase III/IIIb; 2) The intervention is radiotherapy alone, with no drug-containing intervention specified. The primary endpoint was neurocognitive function, not a time-to-event efficacy endpoint, though overall survival was a secondary endpoint.
摘要

摘要

AIMS: To assess in patients with 1-10 brain metastases, each of which has been treated by neurosurgery or stereotactic radiosurgery, whether hippocampal sparing whole brain radiotherapy (HS-WBRT) better spares neurocognitive function (NCF) than standard WBRT. Further, to assess whether a phase III randomised trial of HS-WBRT would be feasible in the UK. MATERIALS AND METHODS: A multicentre, randomised, open label phase II trial was undertaken, randomising patients to 30Gy in 10 fractions of WBRT or HS-WBRT. The primary endpoint was decline in Total recall using Hopkins Verbal Learning Test Revised (HVLT-R) at 4 months post treatment. To assess this, we aimed to recruit 84 patients over 3 years. Secondary endpoints included further measures of NCF, quality of life, duration of functional independence, local control of treated metastases, development of new metastases, disease control within the hippocampal regions, overall survival, steroid and antiepileptic medication requirements, and toxicity. RESULTS: The trial closed prematurely due to slower than anticipated recruitment. From April 2016 to January 2018, 23 patients were randomised. Follow up was a median of 25 months. Fifteen patients (6 WBRT, 9 HS-WBRT) were assessed for the primary endpoint; of these, 1 in each arm experienced significant decline in the 4-month HVLT-R Total recall score (p = 0.8). Patients in the HS-WBRT arm experienced less insomnia (p < 0.01) and drowsiness (p < 0.01). There were no differences in other secondary endpoints. CONCLUSION: A phase III randomised trial of HS-WBRT was shown not to be feasible at this time in the UK. As most randomised trials of HS-WBRT reported to date share common endpoints, including NCF, an individual patient data meta-analysis should be undertaken.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。